Metformin effects on FOXP3+ and CD8+ T cell infiltrates of head and neck squamous cell carcinoma
The Laryngoscope Oct 14, 2019
Amin D, Richa T, Mollaee M, et al. - Using Visiopharm software in this retrospective analysis, researchers studied the impact of metformin on immune cell infiltrates of head and neck squamous cell carcinoma (HNSCC). Metformin was titrated to a standard diabetic dose (2000 mg/day) for at least 9 days before surgical resection (mean 13.6 days). From 36 individuals (16 HPV+, 20 HPV−), pre and posttreatment surgical specimens have been comparatively analyzed. Metformin treatment was linked to a 41.4% reduction in FOXP3+ T cells in intratumor regions of interest and a 66.5% rise in stromal CD8+ T cells at the leading edge of the tumor relative to pretreatment biopsies. This was expressed in increased CD8+/FOXP3+ cell ratios within the tumor and stromal compartments. Findings suggested that treatment with metformin could favorably alter the HNSCC immune tumor microenvironment regardless of HPV status.
Go to Original
Only Doctors with an M3 India account can read this article. Sign up for free or login with your existing account.
4 reasons why Doctors love M3 India
-
Exclusive Write-ups & Webinars by KOLs
-
Daily Quiz by specialty
-
Paid Market Research Surveys
-
Case discussions, News & Journals' summaries